Genfit (GNFT) Competitors $3.62 +0.07 (+2.11%) As of 03/28/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNFT vs. AVBP, ORGO, CVAC, GHRS, NUVB, CRMD, IMNM, ABUS, BCYC, and DNTHShould you be buying Genfit stock or one of its competitors? The main competitors of Genfit include ArriVent BioPharma (AVBP), Organogenesis (ORGO), CureVac (CVAC), GH Research (GHRS), Nuvation Bio (NUVB), CorMedix (CRMD), Immunome (IMNM), Arbutus Biopharma (ABUS), Bicycle Therapeutics (BCYC), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry. Genfit vs. ArriVent BioPharma Organogenesis CureVac GH Research Nuvation Bio CorMedix Immunome Arbutus Biopharma Bicycle Therapeutics Dianthus Therapeutics ArriVent BioPharma (NASDAQ:AVBP) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Do analysts recommend AVBP or GNFT? ArriVent BioPharma currently has a consensus price target of $39.00, suggesting a potential upside of 105.80%. Genfit has a consensus price target of $13.00, suggesting a potential upside of 258.72%. Given Genfit's higher possible upside, analysts clearly believe Genfit is more favorable than ArriVent BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Genfit 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor AVBP or GNFT? In the previous week, ArriVent BioPharma had 8 more articles in the media than Genfit. MarketBeat recorded 10 mentions for ArriVent BioPharma and 2 mentions for Genfit. Genfit's average media sentiment score of 0.93 beat ArriVent BioPharma's score of 0.93 indicating that Genfit is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genfit 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, AVBP or GNFT? Genfit has higher revenue and earnings than ArriVent BioPharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArriVent BioPharmaN/AN/A-$69.33M-$2.57-7.37Genfit$76.06M2.38-$31.27MN/AN/A Is AVBP or GNFT more profitable? Genfit's return on equity of 0.00% beat ArriVent BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets ArriVent BioPharmaN/A -43.89% -29.67% Genfit N/A N/A N/A Do insiders and institutionals hold more shares of AVBP or GNFT? 9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 2.2% of Genfit shares are held by institutional investors. 4.2% of Genfit shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, AVBP or GNFT? ArriVent BioPharma has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Genfit has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Does the MarketBeat Community prefer AVBP or GNFT? Genfit received 48 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 69.70% of users gave Genfit an outperform vote. CompanyUnderperformOutperformArriVent BioPharmaOutperform Votes21100.00% Underperform VotesNo VotesGenfitOutperform Votes6969.70% Underperform Votes3030.30% SummaryGenfit beats ArriVent BioPharma on 9 of the 15 factors compared between the two stocks. Remove Ads Get Genfit News Delivered to You Automatically Sign up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNFT vs. The Competition Export to ExcelMetricGenfitBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$181.19M$3.03B$5.63B$7.83BDividend YieldN/A1.54%4.57%4.01%P/E RatioN/A28.9323.3318.67Price / Sales2.38429.70388.3491.01Price / CashN/A168.6838.1634.64Price / Book2.453.926.894.23Net Income-$31.27M-$71.95M$3.20B$247.15M7 Day Performance-0.17%-5.55%-2.98%-2.17%1 Month Performance4.44%-11.96%1.63%-5.68%1 Year Performance1.80%-27.81%9.44%-0.74% Genfit Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNFTGenfit2.106 of 5 stars$3.62+2.1%$13.00+258.7%+1.8%$181.19M$76.06M0.00120Upcoming EarningsGap UpAVBPArriVent BioPharma1.4153 of 5 stars$20.21+3.5%$39.00+93.0%+6.1%$687.46MN/A-7.8640ORGOOrganogenesis3.5221 of 5 stars$5.42+11.1%$5.50+1.5%+58.5%$687.41M$482.04M-90.33950CVACCureVac3.8248 of 5 stars$3.00+3.8%$10.00+233.3%-1.7%$671.64M$543.28M5.45880News CoverageGap UpGHRSGH Research2.6628 of 5 stars$12.88+3.0%$30.86+139.6%+3.8%$670.12MN/A-16.3010NUVBNuvation Bio2.0225 of 5 stars$1.96+3.4%$8.33+326.3%-50.1%$662.12M$7.87M-0.9060Analyst ForecastCRMDCorMedix2.6152 of 5 stars$10.77-1.3%$16.00+48.6%+59.0%$653.49M$12.26M-13.3030Earnings ReportAnalyst ForecastOptions VolumeAnalyst RevisionNews CoverageIMNMImmunome1.9642 of 5 stars$8.15-0.4%$25.50+212.9%-71.7%$650.18M$10.13M-1.0040Insider TradeNews CoverageABUSArbutus Biopharma1.4209 of 5 stars$3.39+3.4%$5.50+62.2%+35.7%$642.38M$6.74M-7.8890Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageBCYCBicycle Therapeutics1.9005 of 5 stars$9.20+1.3%$29.14+216.8%-64.0%$636.66M$35.28M-2.80240High Trading VolumeDNTHDianthus Therapeutics1.3583 of 5 stars$19.41-0.4%$54.33+179.9%-33.4%$623.55M$6.24M-7.7680 Remove Ads Related Companies and Tools Related Companies ArriVent BioPharma Alternatives Organogenesis Alternatives CureVac Alternatives GH Research Alternatives Nuvation Bio Alternatives CorMedix Alternatives Immunome Alternatives Arbutus Biopharma Alternatives Bicycle Therapeutics Alternatives Dianthus Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNFT) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genfit S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genfit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GNFT Stock Free GNFT Stock Alerts